The object of this bidding is the contracting of the supply of kits for the early detection of genetic diseases in newborns and the provision of equipment for the processing of 33,000 dried blood samples for neonatal screening for the correct execution of the research project “MetabPlus: a flexible and efficient multi-IEM Newborn Screening Program”, financed by public-private collaboration projects, of the State Plan for Scientific, Technical and Innovation Research 2021-2023, within the framework of the Recovery, Transformation and Resilience Plan.
Thus, the contract referred to in this document will be financed by the project “MetabPlus: a flexible and efficient multi-IEM Newborn Screening Program”; the contract is part of project CPP2022-010108, financed by MCIN/AEI/10.13039/501100011033 and by the European Union-NextGenerationEU/PRTR.
For each sample, enzymatic measurements will be performed to assess its substrate-enzyme activity, and the gene and transcriptomic profile of each will be evaluated.
Additionally, all gene expression assays for the indicated metabolites will be included, allowing the study to be conducted through multiplex technology on pre-designed plates and/or cards, thus reducing reagent consumption by working with the minimum sample volume.
An integrated workflow will be utilized: enzymatic, genomic, and transcriptomic analysis. In order to ensure the reproducibility of the studies, all samples will be analyzed in triplicate for critical determinations.

LOT-0000
Contract for the supply of kits for the early detection of genetic diseases in newborns and provision of equipment.
The object of this bidding is the contracting of the supply of kits for the early detection of genetic diseases in newborns and the provision of equipment for the processing of 33,000 dried blood samples for neonatal screening for the correct execution of the research project “MetabPlus: a flexible and efficient multi-IEM Newborn Screening Program”, financed by public-private collaboration projects, of the State Plan for Scientific, Technical and Innovation Research 2021-2023, within the framework of the Recovery, Transformation and Resilience Plan.
Thus, the contract referred to in this document will be financed by the project “MetabPlus: a flexible and efficient multi-IEM Newborn Screening Program”; the contract is part of project CPP2022-010108, financed by MCIN/AEI/10.13039/501100011033 and by the European Union-NextGenerationEU/PRTR.
For each sample, enzymatic measurements will be performed to assess its substrate-enzyme activity, and the gene and transcriptomic profile of each will be evaluated.
Additionally, all gene expression assays for the indicated metabolites will be included, allowing the study to be conducted through multiplex technology on pre-designed plates and/or cards, thus reducing reagent consumption by working with the minimum sample volume.
An integrated workflow will be utilized: enzymatic, genomic, and transcriptomic analysis. In order to ensure the reproducibility of the studies, all samples will be analyzed in triplicate for critical determinations.